

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

For the month of January 2017

Commission File Number 001-37626

---

**Mesoblast Limited**

*(Exact name of Registrant as specified in its charter)*

---

**Not Applicable**

*(Translation of Registrant's name into English)*

**Australia**

*(Jurisdiction of incorporation or organization)*

**Silviu Itescu**

**Chief Executive Officer and Executive Director**

**Level 38**

**55 Collins Street**

**Melbourne 3000**

**Australia**

*(Address of principal executive offices)*

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

---

---

**INFORMATION CONTAINED ON THIS REPORT ON FORM 6-K**

On January 11, 2017, Mesoblast Limited filed with the Australian Securities Exchange a new release announcement, which is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized.

MESOBLAST LIMITED

/s/ Charlie Harrison

Charlie Harrison

*Company Secretary*

---

Dated: January 12, 2017

---

## INDEX TO EXHIBITS

Item

99.1 Press release of Mesoblast Ltd, dated January 11, 2017.

**MESOBLAST TO PRESENT AT 35<sup>TH</sup> ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE**

**Melbourne, Australia; and New York, USA; January 11, 2017:** Mesoblast (ASX: MSB; Nasdaq: MESO) will host a live audio webcast at the 35<sup>th</sup> Annual J.P. Morgan Healthcare Conference. Mesoblast's management will present on Thursday, January 12, 2017 at 7:30 AM PST/2.30 a.m. Friday, January 13, 2017 (AEDT).

**What:** Mesoblast Presentation at the 35<sup>th</sup> Annual J. P. Morgan Healthcare Conference

**When:** Thursday, January 12, 2017 at 7.30 a.m. PST/2.30 a.m. Friday, January 13, 2017 (AEDT).

**Where:** <http://jpmorgan.metameetings.com/confbook/healthcare17/directlink?p=22962>

**How:** Log on to the live webcast at the address above and register for the event approximately 10 minutes before the scheduled start time. The archived webcast will be available in the Events and Presentations section of the Company's website ([www.mesoblast.com](http://www.mesoblast.com)).

**About Mesoblast**

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.

**Forward-Looking Statements**

This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

*For further information, please contact:*

Julie Meldrum  
 Corporate Communications  
 T: +61 3 9639 6036  
 E: [julie.meldrum@mesoblast.com](mailto:julie.meldrum@mesoblast.com)

Schond Greenway  
 Investor Relations  
 T: +1 212 880 2060  
 E: [schond.greenway@mesoblast.com](mailto:schond.greenway@mesoblast.com)

**Mesoblast Limited**  
 ABN 68 109 431 870  
[www.mesoblast.com](http://www.mesoblast.com)

**Corporate Headquarters**  
 Level 38  
 55 Collins Street  
 Melbourne 3000  
 Victoria Australia

T +61 3 9639 6036  
 F +61 3 9639 6030

**United States Operations**  
 505 Fifth Avenue  
 Third Floor  
 New York, NY 10017  
 USA

T +1 212 880 2060  
 F +1 212 880 2061

**Asia**  
 20 Biopolis Way  
 #05-01 Centros  
 Biopreneur 3  
 SINGAPORE 138668

T +65 6570 0635  
 F +65 6570 0176